// App-Quantinova.ai

S4091 2016 AHA : Eligibility for Ivabradine in Heart Failure: Representativeness of SHIFT in a Broad Population

Researchers

Presenter

  • Gianluigi Savarese

Principal Investigators

  • Ulf Dahlstrom

  • Michael Fu

  • Jonathan G Howlett

  • Justin A Ezekowitz

  • Lars H Lund

Medical Centers

  • Univ of Calgary, Calgary, Canada

  • University of Naples Federico II, Naples, Italy

  • Linkoping University, Linkoping, Sweden

  • Karolinska University Hospital, Stockholm, Sweden

  • Univ. of Alberta, Edmonton, Alberta, Canada.

  • Univ of Gothenburg, Goteborg, Sweden

Locations

  • Canada

  • Sweden

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Coronary Artery Disease

  • Congestive heart failure

  • Arrhythmia

  • Diabetes

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • Ivabradine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved